Colorectal cancer (CRC) is highly heterogeneous at the genetic and molecular level, which
has major repercussions on the efficacy of immunotherapy. A small subset of CRCs exhibit …

Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only
a fraction of patients with cancer responds to immunotherapy, and currently available …

Tumor-infiltrating immune cells (TIICs) play essential roles in cancer development and
progression. However, the association of TIICs with prognosis in colorectal cancer (CRC) …

CD39 is an enzyme which is responsible, together with CD73, for a cascade converting
adenosine triphosphate into adenosine diphosphate and cyclic adenosine monophosphate …

The tumor microenvironment restrains conventional T cell (Tconv) activation while facilitating
the expansion of Tregs. Here we showed that Tregs' advantage in the tumor milieu relies on …

Tumor-infiltrating immune cells are closely associated with clinical outcome. However,
immunohistochemistry-based analysis of tumor infiltrates can be misleading as the …

Our understanding of tumor-infiltrating lymphocytes (TILs) is rapidly expanding beyond T cell-
centric perspectives to include B cells and plasma cells, collectively referred to as TIL-Bs. In …

In recent years, monoclonal antibodies (mAbs) able to reinvigorate antitumor T-cell immunity
have heralded a paradigm shift in cancer treatment. The most high profile of these mAbs …

Abstract Background/Aims: Hypoxia occurs in many pathological conditions, including
inflammation and cancer. Within this context, hypoxia was shown to inhibit but also to …

Abstract The programmed death (PD)‐1/PD‐ligand (PD‐L) pathway and regulatory T cells
(Tregs) are essential for the maintenance of immune tolerance. Their activation in the tumour …